Serum 6-bromotryptophan levels identified as a risk factor for CKD progression
Journal of the American Society of Nephrology Jun 01, 2018
Tin A, et al. - In participants of the African American Study of Kidney Disease and Hypertension (AASK), researchers assessed the links between the number of APOL1 risk alleles and 760 serum metabolites identified via untargeted profiling. They also replicated findings in 678 black participants with CKD in BioMe, an electronic medical record–linked biobank. They tested the metabolite association with CKD progression in AASK, BioMe, and the Modification of Diet in Renal Disease (MDRD) Study. Serum 6-bromotryptophan was identified as a consistent and novel risk factor for CKD progression. In AASK and BioMe participants and in white participants in the MDRD Study, lower levels of 6-bromotryptophan were found to be related to CKD progression, independent of demographics and clinical characteristics, including baseline GFR.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries